Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
PRNewswire - October 30, 2006
Viral Genetics' VGV-1 is a suspension of thymus nuclear protein that has been tested in several studies in HIV infected individuals. As previously reported, the 137-patient study showed statistically significant antiviral effects in treated subjects vs. placebo 100 days after the completion of dosing. As reported in the Company's poster presentation at the recent XVI International AIDS Conference, VGV-1 treated subjects also demonstrated apparent beneficial immunological changes when compared with placebo.
Results indicate statistically significant antiviral activity in some patients, no serious adverse events observed in relation to VGV-1, and a mechanism of action that may be markedly different than existing HIV therapies. Conclusions of the study also state that bioactivity of VGV-1 was confirmed.
Viral Genetics' next plans are to further determine the product's optimal dosing and to elucidate its mechanism of action.
Additional results and study data are available by request at info@viralgenetics.com. The poster will be made available on the company's website following the conference.
The World Health Organization estimates approximately 40 million people are now living with HIV. Even with the available treatments for AIDS, there are large numbers of people that need alternative therapies and hope remains that progress will be made in discovering new therapies that bolster patients' immune systems.
The 10th Anniversary of The Institute of Human Virology International Meeting has grown into one of the worlds leading HIV/AIDS conferences. Founded in 1996, IHV has positioned itself as one of the world's premier research and development facilities.
About VGV-1
VGV-1 is a therapy based on thymus nuclear protein which is extracted from bovine thymus tissue. As a type of immune-based therapy, it focuses on boosting the immune system to allow the body to fight HIV more efficiently. Discovered and developed by both Dr. Harry Zhabilov Sr. and Harry Zhabilov Jr., thymus nuclear protein technology has been studied in five human clinical trials for the treatment of HIV infection and AIDS.
About Viral Genetics
Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. Online at http://www.viralgenetics.com
For additional information, please contact Kirsten Ayars at 805-452-7909. For investor inquiries, please contact Evan Pondel at 310-279-5973.
This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition and the development of studies and strategies leading to commercialization of VGV-1 in the United States. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.
SOURCE Viral Genetics, Inc.
http://www.viralgenetics.com
061030
PR061034
Copyright © 2006 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .